Ethicann Pharmaceuticals announced a development and commercial supply partnership with Ilera Therapeutics. Ethicann was founded in 2018 as a pharma enterprise with a global focus by executives and investors with extensive experience in the Canadian and U.S. pharmaceutical and Canadian cannabis industries. Ethicann's strict focus is the commercialization of cannabis-based ethical drugs that will be submitted for marketing approvals to Health Canada, the U.S. Food and Drug Administration (FDA) and other global pharma regulatory authorities. Ethicann completed its initial financing earlier this year.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Ilera Therapeutics is part of the Ilera group of companies that are leading licensed growers/extractors of cannabis products in Pennsylvania and Louisiana, selling botanical cannabinoid oils and related products to medical marijuana dispensaries in each state. Moreover, the members of Ilera Therapeutics' management team and Board have highly respected global pharma backgrounds, headed by Chairman Osagie Imasogie--who held senior executive positions at GlaxoSmithKline and Dupont Merck. In their partnership, the two companies share a keen interest in the development and commercialization of cannabis-based pharmaceuticals that target important disease areas and that will be subject to the rigors of global drug regulatory review.
Ilera Therapeutics will develop and manufacture a highly purified botanical THC-based product that can be used by Ethicann to conduct a limited clinical study to support a market approval application that Ethicann will file initially in the United States for its CAN-001 product. Ethicann will then seek approvals in other global markets, using the same clinical data.
CAN-001 is a treatment for chemotherapy-induced nausea and vomiting (CINV), which occurs in approximately 80% of the new 23.6 million cases of cancer annually worldwide. The global market for treating CINV with THC is estimated at USD $2.66 billion.